ArmInfo.A medicinal vaccine against human papillomavirus, which will be used in Armenia in December 2017, was produced by the American company Merc on October 12, 2016 with a shelf life of three years.
As the press service of the Ministry of Health reports, all vaccines underwent laboratory and documentary research in Holland, and only then were imported to Armenia. The National Public Health Commission and the National Institute of the Netherlands have finalized the protocol for the production of vaccines. 34,700 vaccines that passed all the necessary laboratory tests were sent to Armenia with a certificate numbered N 171337.
The certificate states that the vaccine series N 013326, imported to Armenia through the United Nations Children's Fund, meets the requirements of Part A of the World Health Organization guidelines that ensure the safety and efficacy of vaccines containing gene (recombinant) virus-containing ingredients. The certificate also states that this batch of vaccine was produced in accordance with the basic principles of biological products and in accordance with the proper production process.
The results of laboratory tests were also presented. Recombinant vaccines are now considered the safest and most effective. In Armenia, since 2000, a recombinant vaccine has been used to prevent hepatitis B among children under the age of one year.
The vaccine "Gardasil", which will be used in Armenia, protects a person from the main strains of papillomavirus, which subsequently lead to the formation of cervical cancer. In Armenia, vaccination with papillomavirus began in December this year. It makes girls 13 years on a voluntary basis. Parents who refuse to vaccinate are required to provide a written refusal. At the moment, the society in Armenia is doubtful about this vaccine, as there is an opinion that it, preventing the development of the papilloma virus, can subsequently cause complications in children. For example, some believe that the use of this vaccine can lead to infertility, etc.
ArmInfo.Armenia will start vaccination of girls at the age of 13 from virus papilla December 2017 to prevent cervical cancer. The decision on this was taken at a government meeting on November 9.As the Armenian Minister of Health Levon Altunyan stated, starting from the second decade of December of this year to the middle of 2018, vaccination will be carried out.